Identification of OAT1/OAT3 As Contributors to Cisplatin Toxicity

Overview

Journal Clin Transl Sci

Specialties Biomedical Engineering
General Medicine

Date 2017 Jul 10

PMID 28689374

Citations 19

Authors

S Hu

A F Leblanc

A A Gibson

K W Hong

J Y Kim

L J Janke

L Li

A Vasilyeva

D B Finkelstein

J A Sprowl

D H Sweet

E Schlatter

G Ciarimboli

Jhm Schellens

S D Baker

N Pabla

A Sparreboom

Affiliations

Soon will be listed here.

Abstract

Cisplatin is among the most widely used anticancer drugs and known to cause a dose-limiting nephrotoxicity, which is partially dependent on the renal uptake carrier OCT2. We here report a previously unrecognized, OCT2-independent pathway of cisplatin-induced renal injury that is mediated by the organic anion transporters OAT1 and OAT3. Using transporter-deficient mouse models, we found that this mechanism regulates renal uptake of a mercapturic acid metabolite of cisplatin that acts as a precursor of a potent nephrotoxin. The function of these two transport systems can be simultaneously inhibited by the tyrosine kinase inhibitor nilotinib through noncompetitive mechanisms, without compromising the anticancer properties of cisplatin. Collectively, our findings reveal a novel pathway that explains the fundamental basis of cisplatin-induced nephrotoxicity, with potential implications for its therapeutic management.

Citing Articles

Resazurin dye is an in vivo sensor of kidney tubular function.

Martinez S, Karel I, Silvaroli J, Ahmed E, Kim J, Stayton A Kidney Int. 2024; 107(3):508-520.

PMID: 39733791 PMC: 11845305. DOI: 10.1016/j.kint.2024.12.008.

Development of a Highly Differentiated Human Primary Proximal Tubule MPS Model (aProximate MPS Flow).

Pisapia F, OBrien D, Tasinato E, Garner K, Brown C Bioengineering (Basel). 2024; 11(1).

PMID: 38275575 PMC: 10813028. DOI: 10.3390/bioengineering11010007.

The Protective Effect of against Cisplatin-Induced Nephrotoxicity Mediated by Inhibiting Oxidative Stress, Inflammation, and Apoptosis.

Zhang Z, Liang B, Jike W, Li R, Su X, Yu J Molecules. 2023; 28(22).

PMID: 38005304 PMC: 10674371. DOI: 10.3390/molecules28227582.

Polymorphic renal transporters and cisplatin's toxicity in urinary bladder cancer patients: current perspectives and future directions.

Selim M, Kassem A, El-Bassiouny N, Salahuddin A, Abu El-Ela R, Hamza M Med Oncol. 2023; 40(2):80.

PMID: 36650399 PMC: 9845168. DOI: 10.1007/s12032-022-01928-0.

Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma.

Thind A, Ashford B, Strbenac D, Mitchell J, Lee J, Mueller S Front Oncol. 2022; 12:919118.

PMID: 35982973 PMC: 9379253. DOI: 10.3389/fonc.2022.919118.

References

Wen X, Buckley B, McCandlish E, Goedken M, Syed S, Pelis R . Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am J Pathol. 2014; 184(5):1299-308. PMC: 4005989. DOI: 10.1016/j.ajpath.2014.01.025. View

Xia B, Heimbach T, He H, Lin T . Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. Biopharm Drug Dispos. 2012; 33(9):536-49. DOI: 10.1002/bdd.1821. View

Townsend D, Hanigan M . Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther. 2001; 300(1):142-8. PMC: 6522257. DOI: 10.1124/jpet.300.1.142. View

Pabla N, Dong G, Jiang M, Huang S, Kumar M, Messing R . Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest. 2011; 121(7):2709-22. PMC: 3223835. DOI: 10.1172/JCI45586. View

Giacomini K, Huang S, Tweedie D, Benet L, Brouwer K, Chu X . Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3):215-36. PMC: 3326076. DOI: 10.1038/nrd3028. View

Osman N, Litterst C . Effect of probenecid and N'-methylnicotinamide on renal handling of cis-dichlorodiammineplatinum-II in rats. Cancer Lett. 1983; 19(1):107-11. DOI: 10.1016/0304-3835(83)90143-x. View

Wang F, Wang X, Shi C, Zhang H, Hu Y, Chen Y . Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells. Molecules. 2014; 19(3):3356-75. PMC: 6270868. DOI: 10.3390/molecules19033356. View

Townsend D, Deng M, Zhang L, Lapus M, Hanigan M . Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol. 2002; 14(1):1-10. PMC: 6361148. DOI: 10.1097/01.asn.0000042803.28024.92. View

Pabla N, Dong Z . Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008; 73(9):994-1007. DOI: 10.1038/sj.ki.5002786. View

10.

Vallon V, Eraly S, Rao S, Gerasimova M, Rose M, Nagle M . A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol. 2012; 302(10):F1293-9. PMC: 3362066. DOI: 10.1152/ajprenal.00013.2012. View

11.

Sprowl J, Ong S, Gibson A, Hu S, Du G, Lin W . A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 2016; 7:10880. PMC: 4799362. DOI: 10.1038/ncomms10880. View

12.

Bakhiya N, Batke M, Laake J, Monien B, Frank H, Seidel A . Directing role of organic anion transporters in the excretion of mercapturic acids of alkylated polycyclic aromatic hydrocarbons. Drug Metab Dispos. 2007; 35(10):1824-31. DOI: 10.1124/dmd.107.016964. View

13.

Townsend D, Marto J, Deng M, Macdonald T, Hanigan M . High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotransformation products of Cisplatin. Drug Metab Dispos. 2003; 31(6):705-13. PMC: 6522263. DOI: 10.1124/dmd.31.6.705. View

14.

Zhang X, Kyo S, Nakamura M, Mizumoto Y, Maida Y, Bono Y . Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells. Cancer Lett. 2013; 345(1):106-14. DOI: 10.1016/j.canlet.2013.11.020. View

15.

Ross D, GALE G . Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid. Cancer Treat Rep. 1979; 63(5):781-7. View

16.

Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B . Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol. 2010; 176(3):1169-80. PMC: 2832140. DOI: 10.2353/ajpath.2010.090610. View

17.

Franke R, Kosloske A, Lancaster C, Filipski K, Hu C, Zolk O . Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res. 2010; 16(16):4198-206. PMC: 3514415. DOI: 10.1158/1078-0432.CCR-10-0949. View

18.

Hu S, Mathijssen R, de Bruijn P, Baker S, Sparreboom A . Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer. 2014; 110(4):894-8. PMC: 3929889. DOI: 10.1038/bjc.2013.811. View

19.

Jacobs C, Coleman C, Rich L, Hirst K, Weiner M . Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Res. 1984; 44(8):3632-5. View

20.

Johnston R, Rawling T, Chan T, Zhou F, Murray M . Selective inhibition of human solute carrier transporters by multikinase inhibitors. Drug Metab Dispos. 2014; 42(11):1851-7. DOI: 10.1124/dmd.114.059097. View